NUP85 Antibody

What is NUP85 and why is it important in cellular research?

NUP85 is a critical 75 kDa nucleoporin protein component of the Nup107-160 subcomplex within the nuclear pore complex (NPC). This protein plays essential roles beyond mere nucleocytoplasmic transport, functioning in mitotic machinery regulation, transcription control, and chromatin organization through transport-independent mechanisms. The Nup107-160 complex, of which NUP85 is a key member, contributes fundamentally to the assembly and maintenance of NPC structure. Research interest in NUP85 has increased due to its association with kinetochores, mitotic spindles, centrosomes, and mitotic checkpoint regulators necessary for proper cell cycle completion. Functional studies have demonstrated that downregulation of NUP107-160 subcomplex components, including NUP85, results in defective cytokinesis, compromised microtubule structures, altered cytoskeletal dynamics, and impaired chromosome segregation and differentiation . Additionally, pathological relevance has emerged with the discovery that mutations in NUP85 are linked to steroid-resistant nephrotic syndrome and potentially to primary autosomal recessive microcephaly and Seckel syndrome spectrum disorders .

Which applications are most effective for NUP85 antibody detection in research settings?

NUP85 antibodies have been validated across multiple experimental approaches with specific applications demonstrating consistent results:

When selecting an application, consider that WB typically provides quantitative information about protein expression levels, while immunofluorescence offers subcellular localization insights. For tissue distribution studies, IHC remains the gold standard. Flow cytometry is particularly useful when analyzing NUP85 expression across heterogeneous cell populations. Antibody selection should be guided by the specific experimental question, with polyclonal antibodies offering high sensitivity and recombinant antibodies providing superior reproducibility across experiments .

What are the optimal sample preparation conditions for NUP85 antibody applications?

Optimal sample preparation varies by technique but follows general principles for nuclear protein detection:

For Western Blot:

• Complete cell lysis requires stronger buffers (RIPA or NP-40 with protease inhibitors)

• Nuclear fractionation may improve signal detection

• Sample denaturation at 95°C for 5 minutes in loading buffer (containing SDS and DTT) is recommended

• Loading 25-50 μg of total protein typically yields detectable signals

For Immunohistochemistry:

• Fixed tissue sections benefit from antigen retrieval with TE buffer pH 9.0 for optimal epitope exposure

• Alternative retrieval with citrate buffer pH 6.0 may be performed if necessary

• Fixation with 4% paraformaldehyde shows consistent results

• For paraffin sections, dilutions of 1:250-1:1000 are recommended

For Immunofluorescence:

• Fixation with 4% paraformaldehyde (10-15 minutes) followed by permeabilization (0.1-0.5% Triton X-100)

• Blocking with 1-5% BSA or normal serum for 30-60 minutes reduces non-specific binding

• Overnight primary antibody incubation at 4°C often improves signal-to-noise ratio

• Recommended dilutions range from 1:125-1:800 depending on the specific antibody clone

Each application requires optimization for specific experimental systems, and researchers should perform titration experiments to determine optimal conditions.

How can researchers address epitope accessibility challenges when using NUP85 antibodies in complex nuclear structures?

Accessing NUP85 epitopes within the intricate nuclear pore complex presents unique challenges requiring specialized approaches:

• Strategic Permeabilization Protocols: Standard Triton X-100 permeabilization may be insufficient for complete nuclear envelope access. Sequential permeabilization using graduated concentrations (0.1% followed by 0.3%) or alternative detergents like digitonin (25-50 μg/ml) selectively permeabilizes plasma membranes while preserving nuclear envelope structure. For complete nuclear pore access, late-stage permeabilization with 0.5% Triton X-100 provides more thorough epitope exposure.

• Targeted Antigen Retrieval for Fixed Tissues: For NUP85 detection in tissue sections, standard citrate buffer retrieval often yields suboptimal results. Evidence suggests that TE buffer at pH 9.0 significantly improves epitope accessibility, particularly for the conformational epitopes present in the protein's structured domains. This higher pH retrieval enables detection of NUP85 in complex tissues like brain and testis .

• Chromatin Clearing Techniques: As NUP85 interacts with chromatin during mitosis, pre-treatment with limited nuclease digestion (DNase I at 10-50 μg/ml, 15-30 minutes at 37°C) can reduce molecular crowding around nuclear pore complexes, improving antibody penetration and signal specificity in densely packed chromatin regions during nuclear envelope reassembly phases.

• Combinatorial Epitope Targeting: Given that different NUP85 antibodies target distinct epitopes (e.g., recombinant antibody 83288-1-RR versus polyclonal 19370-1-AP), using multiple antibodies simultaneously can provide comprehensive detection across conformational states and interaction complexes. This is particularly valuable when studying NUP85's dual roles in NPC structure and mitotic progression .

Implementation of these advanced approaches requires careful validation through appropriate controls, including competitive peptide blocking and parallel experiments with different fixation methods.

What strategies can resolve discrepancies between calculated (75 kDa) and observed (60-75 kDa) molecular weights of NUP85 in Western blot analysis?

Molecular weight discrepancies between predicted and observed NUP85 proteins represent a common challenge in research applications. Several methodological approaches can address this issue:

• Post-translational Modification Analysis: NUP85 undergoes various modifications that alter migration patterns. Phosphatase treatment (λ-phosphatase, 400 U, 30 minutes at 30°C) prior to SDS-PAGE can determine if phosphorylation contributes to molecular weight variability. Similarly, deglycosylation enzymes (PNGase F) can identify glycosylation contributions to apparent molecular weight.

• Sample Preparation Optimization: Observed molecular weight of 60 kDa (with antibody 15027-1-AP) versus 70-75 kDa (with 19370-1-AP) suggests epitope-specific detection or sample-dependent proteolysis . Comparison of different lysis buffers (RIPA versus urea-based extraction) can determine if extraction method affects observed weight. Addition of broad-spectrum protease inhibitors (including those targeting nuclear proteases) during preparation is essential.

• Resolution Enhancement Techniques:

  • Gradient gels (4-12% or 4-15%) improve separation in the 60-75 kDa range

  • Extended SDS-PAGE running times at lower voltage (80-100V) enhance band resolution

  • Alternative gel systems (Tris-Acetate versus Bis-Tris) may better resolve size variants

• Isoform Identification Approach: The discrepancy may represent detection of different NUP85 isoforms. RNA-seq analysis of your experimental system combined with isoform-specific primers for RT-PCR can confirm expression of specific variants. Cross-validation with multiple antibodies targeting different epitopes helps establish isoform identity.

The observed 60 kDa band detected with antibody 15027-1-AP versus the 70-75 kDa band seen with 19370-1-AP suggests that careful selection of antibodies and validation across multiple systems is critical when quantifying NUP85 expression levels.

How can researchers effectively distinguish between NUP85's structural versus functional roles using antibody-based approaches?

Differentiating between NUP85's structural contributions to NPC architecture and its dynamic functional roles requires sophisticated experimental designs:

• Temporal Dynamics Analysis:

  • Synchronize cells (double thymidine block or nocodazole treatment)

  • Perform time-course immunofluorescence microscopy using NUP85 antibodies (83288-1-RR at 1:250 dilution) in combination with cell cycle markers

  • Co-stain with phospho-histone H3 (mitosis), cyclin B1 (G2/M transition), and EdU incorporation (S-phase)

  • This approach reveals redistribution of NUP85 from NPCs to kinetochores/spindles during cell cycle progression

• Proximity Ligation Assays (PLA):

  • Utilize NUP85 antibodies in conjunction with antibodies against known interacting partners

  • Structural interactions: NUP85 + other Nup107-160 components (SEC13, NUP160)

  • Functional interactions: NUP85 + mitotic regulators (Aurora B, MAD1/2)

  • PLA signal quantification provides spatial and temporal information about interaction contexts

• Sequential Extraction Protocol:

  • Fractionate cells using increasing detergent strengths (digitonin → Triton X-100 → high salt → nuclease)

  • Analyze NUP85 distribution between fractions using antibody 19370-1-AP (1:1000 dilution)

  • Structural pool: resistant to extraction, remains in insoluble fraction

  • Functional pool: extracted in earlier fractions, associated with regulatory complexes

  • This biochemical approach separates stable structural from dynamic functional pools

• Chromatin Immunoprecipitation (ChIP):

  • Utilize NUP85 antibodies (15027-1-AP) for ChIP-seq analysis

  • Identify genomic regions associated with NUP85 beyond NPC localization

  • Correlate with transcriptionally active regions (H3K4me3, RNA Pol II)

  • This approach reveals NUP85's roles in gene expression regulation

Implementation of these complementary approaches provides multidimensional insights into NUP85's dual roles, distinguishing between its constitutive structural functions and its regulatory activities throughout the cell cycle.

What are the most effective strategies for optimizing NUP85 antibody signal-to-noise ratio in immunofluorescence applications?

Achieving optimal signal-to-noise ratio for NUP85 detection requires systematic optimization:

• Antibody Selection and Validation:

  • Different clones show variable performance in IF applications:

    • 83288-1-RR (recombinant) demonstrates superior specificity in HepG2 cells (1:125-1:500)

    • 15027-1-AP shows reliable detection in U2OS and MCF-7 cells (1:200-1:800)

    • 19370-1-AP performs well in hTERT-RPE1 cells (1:20-1:200)

  • Validate specificity through siRNA knockdown or CRISPR knockout controls

• Sample Preparation Optimization:

  • Fixation method significantly impacts epitope preservation:

    • 4% paraformaldehyde (10 min) preserves structure but may mask epitopes

    • Methanol fixation (-20°C, 10 min) enhances nuclear pore detection

    • Combination fixation (2% PFA followed by methanol) often provides optimal results

  • Permeabilization requires balance between access and structure preservation:

    • 0.1-0.2% Triton X-100 (10 min) for general applications

    • 0.005% digitonin for selective plasma membrane permeabilization

    • 0.5% saponin for reversible permeabilization during longer protocols

• Signal Amplification Systems:

  • Tyramide signal amplification (TSA) enhances detection of low-abundance epitopes

  • Secondary antibody selection impacts sensitivity:

    • Highly cross-adsorbed secondaries reduce background

    • F(ab')2 fragments minimize non-specific binding in co-staining experiments

    • Fluorophore selection (Alexa Fluor 488 versus 568) affects signal-to-noise ratio

• Image Acquisition Parameters:

  • Optimal confocal settings for NUP85 detection:

    • Pinhole: 1-1.2 Airy units

    • Line averaging: 4-8 passes

    • Sequential scanning when co-staining with multiple antibodies

    • Z-stack acquisition with 0.3-0.5 μm steps for complete nuclear pore analysis

Implementation of these strategies systematically improves NUP85 detection quality, particularly for distinguishing between nuclear envelope localization versus mitotic redistribution patterns.

How should researchers address potential cross-reactivity concerns when using NUP85 antibodies in multi-protein complex studies?

Addressing cross-reactivity challenges in NPC studies requires strategic experimental design:

• Comprehensive Validation Protocol:

  • Implement a tiered validation approach:

    • Primary validation: Western blot with recombinant NUP85 protein

    • Secondary validation: Detection in NUP85 knockout/knockdown systems

    • Tertiary validation: Peptide competition assays using immunizing peptide

  • The specificity of antibody 19370-1-AP has been validated through published knockout studies

• Cross-Adsorption Techniques:

  • Pre-adsorb antibodies against related nucleoporins (particularly other Nup107-160 complex members)

  • Implement sequential immunodepletion to remove potentially cross-reactive antibodies

  • Test for reactivity against recombinant proteins of structurally similar nucleoporins

• Multiplexed Detection Strategies:

  • Employ dual-labeling with antibodies targeting different NUP85 epitopes:

    • Co-localization confirms specificity (use 15027-1-AP and 19370-1-AP simultaneously)

    • Differential localization patterns may indicate cross-reactivity or isoform specificity

  • Combine with orthogonal detection methods like proximity ligation assays

  • Include comprehensive controls:

    • Single primary antibody controls

    • Secondary-only controls

    • Isotype-matched irrelevant antibody controls

• Advanced Analytical Approaches:

  • Mass spectrometry analysis of immunoprecipitated complexes to confirm target identity

  • Fluorescence resonance energy transfer (FRET) to verify molecular proximity

  • Super-resolution microscopy (STED, STORM) to resolve closely associated NPC components

  • These approaches can differentiate between true NUP85 signal and detection of associated proteins

Implementation of these strategies ensures reliable differentiation between specific NUP85 detection and potential cross-reactivity with other nucleoporins, particularly important when studying the Nup107-160 subcomplex where multiple proteins share structural similarities.

How can NUP85 antibodies be effectively employed in studying its role in nephrotic syndrome and microcephaly spectrum disorders?

Recent discoveries linking NUP85 mutations to steroid-resistant nephrotic syndrome (SRNS), primary autosomal recessive microcephaly, and Seckel syndrome spectrum disorders present new research opportunities requiring specialized approaches :

• Tissue-Specific Detection Protocols:

  • Kidney tissue analysis:

    • Optimize antigen retrieval using TE buffer pH 9.0 for formalin-fixed kidney sections

    • Implement dual IF staining with NUP85 antibody (19370-1-AP at 1:100) and podocyte markers (nephrin, podocin)

    • Correlate NUP85 expression/localization with filtration barrier integrity

  • Neural tissue examination:

    • For microcephaly studies, combine NUP85 detection (15027-1-AP at 1:250) with neural progenitor markers

    • Analyze nuclear envelope morphology in patient-derived versus control neural cells

    • Quantify nuclear size and NPC density using semi-automated image analysis

• Patient-Derived Model Systems:

  • Validate antibody performance in:

    • Patient-derived fibroblasts (skin biopsy)

    • iPSC-derived podocytes (kidney models)

    • iPSC-derived neural progenitors (microcephaly models)

  • For each model, optimize fixation conditions (4% PFA, 10 min) and antibody concentration

• Mutation-Specific Detection Considerations:

  • Most reported NUP85 mutations cause truncation or structural changes

  • Select antibodies targeting epitopes upstream of mutation sites:

    • For C-terminal truncations, use antibodies targeting N-terminal domains

    • For missense mutations, verify epitope accessibility in the altered protein conformation

  • In cases of protein destabilization, extend primary antibody incubation (overnight, 4°C)

• Functional Correlation Studies:

  • Combine NUP85 immunodetection with assays for:

    • Nuclear transport efficiency (importin/exportin cargo localization)

    • DNA damage response (γH2AX foci quantification)

    • Cell cycle progression (EdU incorporation, cyclin expression)

  • These combined approaches link NUP85 alterations to disease-relevant cellular phenotypes

Implementation of these disease-focused protocols enables researchers to connect NUP85 dysfunction to pathological mechanisms in kidney and neurodevelopmental disorders, potentially revealing therapeutic targets in these conditions.

What cutting-edge techniques can integrate NUP85 antibody detection with live-cell imaging to study dynamic nuclear pore complex behaviors?

Emerging technologies enable unprecedented insights into NUP85 dynamics:

• Correlative Live-Cell Immunofluorescence (CLEM) Approach:

  • Initial live imaging of cells expressing fluorescently-tagged nuclear envelope markers

  • Rapid fixation at precise time points using on-stage perfusion systems

  • Subsequent immunofluorescence with NUP85 antibodies (83288-1-RR at 1:250 dilution)

  • This approach correlates dynamic behaviors with NUP85 localization at specific timepoints

• Intrabody-Based Live Detection Systems:

  • Generate cell-permeable nanobodies derived from NUP85 antibodies

  • Conjugate with minimally disruptive fluorophores (SNAP-tag, HaloTag)

  • This enables direct visualization of endogenous NUP85 without genetic modification

  • Monitor redistribution during mitosis, nuclear assembly, and stress responses

• Complementary Proximity Biotinylation Techniques:

  • Combine antibody detection with TurboID or BioID proximity labeling

  • Map temporal changes in NUP85 interaction networks during cell cycle progression

  • Correlate with super-resolution microscopy data using NUP85 antibodies

  • This multi-modal approach connects structural organization with functional interactions

• Cryo-Electron Tomography Integration:

  • Perform correlative cryo-electron tomography with immunogold-labeled NUP85

  • Provide nanometer-resolution insights into NUP85 positioning within NPCs

  • Connect with light microscopy data using fiducial markers

  • This approach bridges molecular-scale organization with cellular-scale dynamics

These cutting-edge approaches represent the future of NUP85 research, enabling integration of structural, dynamic, and functional data across spatial and temporal scales.